PROTHENA CORP PLC (PRTA) Stock News
NASDAQ:PRTA - Nasdaq - IE00B91XRN20 - Common Stock - Currency: USD
PRTA Latest News, Press Relases and Analysis
Top movers in Friday's after hours session
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. Recursion revealed disappointing first-quarter earnings on Monday and announced it would pare down its development pipeline.
TORM plc (TRMD): Among Cheap Rising Stocks to Buy Right Now
We recently published a list of the 10 Cheap Rising Stocks to Buy Right Now. In this article, we will look at where TORM plc (NASDAQ:TRMD) stands against other cheap rising stocks in which to invest. On May 2, US stocks notched their longest winning streak since 2004 as the United States and China signaled […]
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -21.74% and 86.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BOLT
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
Prothena to Report First Quarter 2025 Financial Results on May 8
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Prothena Announces Board of Directors Update
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients.
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
